미주신경 자극 시장 : 업계 동향과 예측(-2029년)

Global vagus nerve stimulation market is projected to register a substantial CAGR of 15.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation

Global Vagus Nerve Stimulation Market, By Product Type (Implantable VNS Devices and External VNS Devices), Biomaterial (Ceramics, Metallic, and Polymerics), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression and Anxiety, and Others), Patient Type (Adults, Pediatric, and Geriatric), End User (Hospitals, Ambulatory Surgical Centers, Specialty Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Philippines, Indonesia, Rest of Asia-Pacific, UAE, Israel, South Africa, Saudi Arabia, Egypt, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the global vagus nerve stimulation market are:

Increasing prevalence and incidence of neurological disorders

Innovative non-invasive Vagus Nerve Stimulation (nVNS) devices introduced to meet the demand

Rise in product approvals

Product development in recent years

Market Players

Some of the key market players in the global vagus nerve stimulation market are listed below:

electroCore, Inc.

LivaNova PLC

Medtronic

SetPoint Medical

tVNS Technologies GmbH

MicroTransponder Inc.

Neuropix

Others

TABLE OF CONTENTS

1 INTRODUCTION 41

• 1.1 OBJECTIVES OF THE STUDY 41
• 1.2 MARKET DEFINITION 41
• 1.3 OVERVIEW OF GLOBAL VAGUS NERVE STIMULATION MARKET 41
• 1.4 LIMITATIONS 43
• 1.5 MARKETS COVERED 43

2 MARKET SEGMENTATION 45

• 2.1 MARKETS COVERED 45
• 2.2 GEOGRAPHICAL SCOPE 46
• 2.3 YEARS CONSIDERED FOR THE STUDY 47
• 2.4 CURRENCY AND PRICING 47
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
• 2.6 MULTIVARIATE MODELLING 51
• 2.7 LIFELINE CURVE , BY PRODUCT TYPE 51
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
• 2.9 DBMR MARKET POSITION GRID 53
• 2.10 MARKET APPLICATION COVERAGE GRID 54
• 2.11 VENDOR SHARE ANALYSIS 55
• 2.12 SECONDARY SOURCES 56
• 2.13 ASSUMPTIONS 56

3 EXECUTIVE SUMMARY 57

4 PREMIUM INSIGHTS 60

• 4.1 PORTER'S FIVE FORCES 63
• 4.2 PESTEL ANALYSIS 64
• 4.3 KEY STRATEGIC INITIATIVES 65

5 REGULATIONS OF GLOBAL VAGUS NERVE STIMULATION MARKET 66

6 MARKET OVERVIEW 70

• 6.1 DRIVERS 72
  • 6.1.1 INCREASING PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS 72
  • 6.1.2 INNOVATIVE NON-INVASIVE VAGUS NERVE STIMULATION DEVICES INTRODUCED TO MEET DEMAND 73
  • 6.1.3 RISE IN PRODUCT APPROVALS 73
  • 6.1.4 PRODUCT DEVELOPMENT IN RECENT YEARS 74
• 6.2 RESTRAINTS 74
  • 6.2.1 HIGH MAINTENANCE AND DEVICE COSTS TO RESTRAIN ADOPTION OF VAGUS NERVE STIMULATORS 74
  • 6.2.2 RISE IN PRODUCT RECALL 75
  • 6.2.3 UNFAVORABLE REIMBURSEMENT POLICIES 75
• 6.3 OPPORTUNITIES 76
  • 6.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 76
  • 6.3.2 RISING GOVERNMENT INITIATIVES FOR NEUROLOGICAL DISEASE 76
• 6.4 CHALLENGES 77
  • 6.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES 77
  • 6.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS 77
  • 6.4.3 STRINGENT REGULATIONS FOR APPROVAL OF MEDICAL DEVICES 78

7 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE 79

• 7.1 OVERVIEW 80
• 7.2 IMPLANTABLE VNS DEVICE 83
• 7.3 EXTERNAL VNS DEVICE 83

8 GLOBAL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL 84

• 8.1 OVERVIEW 85
• 8.2 METALLIC 88
• 8.3 POLYMERIC 88
• 8.4 CERAMICS 89

9 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION 90

• 9.1 OVERVIEW 91
• 9.2 EPILEPTIC SEIZURES 94
  • 9.2.1 IMPLANTABLE VNS DEVICE 94
  • 9.2.2 EXTERNAL VNS DEVICE 94
• 9.3 DEPRESSION AND ANXIETY 94
  • 9.3.1 IMPLANTABLE VNS DEVICE 95
  • 9.3.2 EXTERNAL VNS DEVICE 95
• 9.4 PAIN MANAGEMENT 96
  • 9.4.1 IMPLANTABLE VNS DEVICE 96
  • 9.4.2 EXTERNAL VNS DEVICE 96
• 9.5 OBESITY MANAGEMENT 97
  • 9.5.1 IMPLANTABLE VNS DEVICE 97
  • 9.5.2 EXTERNAL VNS DEVICE 97
• 9.6 OTHERS 98

10 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE 99

• 10.1 OVERVIEW 100
• 10.2 ADULTS 103
  • 10.2.1 IMPLANTABLE VNS DEVICES 103
  • 10.2.2 EXTERNAL VNS DEVICES 103
• 10.3 GERIATRIC 104
  • 10.3.1 IMPLANTABLE VNS DEVICES 104
  • 10.3.2 EXTERNAL VNS DEVICES 104
• 10.4 PEDIATRIC 105
  • 10.4.1 IMPLANTABLE VNS DEVICES 105
  • 10.4.2 EXTERNAL VNS DEVICES 105

11 GLOBAL VAGUS NERVE STIMULATION MARKET, BY END USER 106

• 11.1 OVERVIEW 107
• 11.2 SPECIALTY CENTERS 110
• 11.3 HOSPITALS 110
• 11.4 AMBULATORY SURGICAL CENTERS (ASCS) 111
• 11.5 OTHERS 111

12 GLOBAL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL 112

• 12.1 OVERVIEW 113
• 12.2 DIRECT TENDER 116
• 12.3 RETAIL SALES 116
• 12.4 OTHERS 117

13 GLOBAL VAGUS NERVE STIMULATION MARKET, BY REGION 118

• 13.1 OVERVIEW 119
• 13.2 NORTH AMERICA 124
  • 13.2.1 U.S. 132
  • 13.2.2 CANADA 136
  • 13.2.3 MEXICO 140
• 13.3 EUROPE 144
  • 13.3.1 GERMANY 152
  • 13.3.2 U.K. 156
  • 13.3.3 ITALY 160
  • 13.3.4 SPAIN 164
  • 13.3.5 FRANCE 168
  • 13.3.6 SWITZERLAND 172
  • 13.3.7 BELGIUM 176
  • 13.3.8 NETHERLANDS 180
  • 13.3.9 RUSSIA 184
  • 13.3.10 TURKEY 188
  • 13.3.11 REST OF EUROPE 192
• 13.4 ASIA-PACIFIC 193
  • 13.4.1 CHINA 202
  • 13.4.2 JAPAN 206
  • 13.4.3 SOUTH KOREA 210
  • 13.4.4 INDIA 214
  • 13.4.5 AUSTRALIA 218
  • 13.4.6 SINGAPORE 222
  • 13.4.7 THAILAND 226
  • 13.4.8 MALAYSIA 230
  • 13.4.9 INDONESIA 234
  • 13.4.10 PHILIPPINES 238
  • 13.4.11 REST OF ASIA-PACIFIC 242
• 13.5 SOUTH AMERICA 243
  • 13.5.1 BRAZIL 251
  • 13.5.2 ARGENTINA 255
  • 13.5.3 COLOMBIA 259
  • 13.5.4 REST OF SOUTH AFRICA 263
• 13.6 MIDDLE EAST AND AFRICA 264
  • 13.6.1 SOUTH AFRICA 272
  • 13.6.2 UAE 276
  • 13.6.3 EGYPT 280
  • 13.6.4 SAUDI ARABIA 284
  • 13.6.5 ISRAEL 288
  • 13.6.6 REST OF MIDDLE EAST AND AFRICA 292

14 GLOBAL VAGUS NERVE STIMULATION MARKET: COMPANY LANDSCAPE 293

• 14.1 COMPANY SHARE ANALYSIS: GLOBAL 293
• 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 294
• 14.3 COMPANY SHARE ANALYSIS: EUROPE 295
• 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 296

15 SWOT ANALYSIS 297

16 COMPANY PROFILE 298

• 16.1 ELECTROCORE, INC. 298
  • 16.1.1 COMPANY SNAPSHOT 298
  • 16.1.2 REVENUE ANALYSIS 298
  • 16.1.3 COMPANY SHARE ANALYSIS 299
  • 16.1.4 PRODUCT PORTFOLIO 299
  • 16.1.5 RECENT DEVELOPMENTS 299
• 16.2 LIVANOVA PLC 301
  • 16.2.1 COMPANY SNAPSHOT 301
  • 16.2.2 REVENUE ANALYSIS 301
  • 16.2.3 COMPANY SHARE ANALYSIS 302
  • 16.2.4 PRODUCT PORTFOLIO 302
  • 16.2.5 RECENT DEVELOPMENTS 302
• 16.3 MEDTRONIC 304
  • 16.3.1 COMPANY SNAPSHOT 304
  • 16.3.2 REVENUE ANALYSIS 304
  • 16.3.3 COMPANY SHARE ANALYSIS 305
  • 16.3.4 PRODUCT PORTFOLIO 305
  • 16.3.5 RECENT DEVELOPMENTS 305
• 16.4 SETPOINT MEDICAL 306
  • 16.4.1 COMPANY SNAPSHOT 306
  • 16.4.2 COMPANY SHARE ANALYSIS 306
  • 16.4.3 PRODUCT PORTFOLIO 307
  • 16.4.4 RECENT DEVELOPMENTS 307
• 16.5 TVNS TECHNOLOGIES GMBH 308
  • 16.5.1 COMPANY SNAPSHOT 308
  • 16.5.2 COMPANY SHARE ANALYSIS 308
  • 16.5.3 PRODUCT PORTFOLIO 309
  • 16.5.4 RECENT DEVELOPMENT 309
• 16.6 NEUROPIX COMPANY LTD. 310
  • 16.6.1 COMPANY SNAPSHOT 310
  • 16.6.2 PRODUCT PORTFOLIO 310
  • 16.6.3 RECENT DEVELOPMENT 310
• 16.7 BRAIN CONTROL CO. LTD 311
  • 16.7.1 COMPANY SNAPSHOT 311
  • 16.7.2 PRODUCT PORTFOLIO 311
  • 16.7.3 RECENT DEVELOPMENTS 311
• 16.8 CIRTEC 312
  • 16.8.1 COMPANY SNAPSHOT 312
  • 16.8.2 PRODUCT PORTFOLIO 312
  • 16.8.3 RECENT DEVELOPMENTS 312
• 16.9 MICROTRANSPONDER INC. 313
  • 16.9.1 COMPANY SNAPSHOT 313
  • 16.9.2 PRODUCT PORTFOLIO 313
  • 16.9.3 RECENT DEVELOPMENT 313
• 16.10 PARASYM LTD 314
  • 16.10.1 COMPANY SNAPSHOT 314
  • 16.10.2 PRODUCT PORTFOLIO 314
  • 16.10.3 RECENT DEVELOPMENT 314
• 16.11 RESHAPE LIFESCIENCES INC. (2021) 315
  • 16.11.1 COMPANY SNAPSHOT 315
  • 16.11.2 REVENUE ANALYSIS 315
  • 16.11.3 PRODUCT PORTFOLIO 316
  • 16.11.4 RECENT DEVELOPMENT 316
• 16.12 SOTERIX MEDICAL INC. 317
  • 16.12.1 COMPANY SNAPSHOT 317
  • 16.12.2 PRODUCT PORTFOLIO 317
• 16.13 RECENT DEVELOPMENTS 317

17 QUESTIONNAIRE 318

18 RELATED REPORTS 321